RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Priority Review (China)

Structure/Sequence

Molecular FormulaC13H11N3O4

InChIKeyUVSMNLNDYGZFPF-UHFFFAOYSA-N

CAS Registry19171-19-8

325

Clinical Trials associated with Pomalidomide

NCT07532525

/ RecruitingPhase 1IIT

A Single-Center, Single-Arm, Phase 1 Pilot Study of Pomalidomide Following CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory CD19+ B-Cell Leukemias and Lymphomas

This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia/lymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.

Start Date01 Jul 2026

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

NCT07555938

/ RecruitingPhase 3

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Start Date30 Jun 2026

Sponsor / Collaborator

Roche Holding AG

NCT07463807

/ Not yet recruitingPhase 1/2IIT

Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma

This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving teclistamab and pomalidomide may be safe, tolerable and improve response by lowering myeloma cells to undetectable levels when compared to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with relapsed multiple myeloma.

Start Date26 Jun 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Pomalidomide

100 Translational Medicine associated with Pomalidomide

100 Patents (Medical) associated with Pomalidomide

2,340

Literatures (Medical) associated with Pomalidomide

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-myeloma activity of the CXCR4 antagonist WZ811

Article

Author: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka

Abstract:

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G 0 /G 1 phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.

Key messages:

WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.

01 Jul 2026·ANALYTICA CHIMICA ACTA

Electrochemical platform based on Ti3C2Tx MXene-supported molecularly imprinted polymers for low-level and selective pomalidomide monitoring

Article

Author: Sorkhe, Yahya ; Atici, Esen Bellur ; Cetinkaya, Ahmet ; Sanli, Cansu ; Isa, Ahmed ; Uzunoglu, Aytekin ; Gurbuz, Havva Nur ; Unal, M Altay ; Ozkan, Sibel A

BACKGROUND:

Pomalidomide (POM), a third-generation immunomodulatory drug, is widely used in the therapeutic regimen of multiple myeloma and other hematologic malignancies. Owing to its narrow therapeutic index and substantial interindividual pharmacokinetic variability, accurate quantification of POM in biological matrices is essential to optimize dosing regimens and minimize adverse effects. Conventional analytical systems like HPLC and LC-MS/MS, while highly accurate, can be time-consuming, costly, and technically demanding.

RESULTS:

This study covers the design of a molecularly imprinted polymer (MIP)-based electrochemical sensor incorporating two-dimensional Ti₃C₂T_X MXene nanaolayers (Ti₃C₂T_x NLs) for sensitive and selective detection and quantification of POM. The sensor's performance was enhanced by the integration of Ti₃C₂T_x NLs, followed by modifying a GCE via electropolymerization of its surface with 3-thienylboronic acid (3-TBA) as the functional monomer and aniline (ANI) as a co-monomer. Critical parameters, including the template: monomer ratio, the number of polymerization cycles, and the rebinding time, were systematically optimized. EIS, CV, and SEM analyses were used to confirm the formation of selective recognition cavities and the sensor's electrochemical functionality. The developed MIP sensor exhibited excellent linearity across a concentration range of 1.75 × 10^-13 M to 1.00 × 10^-12 M. It demonstrated outstanding selectivity for POM, even in the presence of structurally similar analogues, co-administered drugs, common biomolecules, and frequently encountered inorganic ions.

SIGNIFICANCE AND NOVELTY:

Overall, this highly sensitive, selective, and cost-effective MIP-based sensor, which demonstrates excellent stability and performance even in complex matrices, provides a robust, practical analytical tool for routine therapeutic drug monitoring of POM in clinical settings. Moreover, the sensor's straightforward fabrication, low operational cost, and reproducible analytical behavior make it a promising alternative to conventional methods, ultimately contributing to more efficient, accessible, and patient-centered therapeutic monitoring platforms.

17 Jun 2026·Journal of the American Chemical Society

Triazenyl Furans as Diels–Alder Dienes

Article

Author: Budwitz, Jessica E. ; Wester, Abigail R. ; Hollers, Skyler A. ; Newton, Christopher G.

2-Triazenyl furans are introduced as bench-stable, electron-rich Diels-Alder dienes, enabling convergent and divergent access to highly substituted arenes under redox-neutral conditions. The triazene substituent activates the furan toward cycloaddition, promotes in situ aromatization, and serves as a versatile handle for downstream functionalization. Diels-Alder reactions are demonstrated with a broad range of dienophiles, including alkenes, alkynes, allenes, and benzyne, in both inter- and intramolecular settings. Chemoselective derivatizations highlight the synthetic versatility of this platform, culminating in concise annulative syntheses of pomalidomide, (S)-apremilast, and related analogues.

563

News (Medical) associated with Pomalidomide

26 Jun 2026

·www.biospace.com

CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI ® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus standard of care 1 Pending approval, this novel complementary immunotherapy combination is positioned to delay disease progression for patients treated as early as second line, with 83% of patients alive at three years 1 BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of an indication extension of TECVAYLI ® (teclistamab) in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. Advancing complementary immunotherapies to improve patient outcomes Teclistamab and daratumumab work in a mechanistically complementary manner by engaging multiple tumour and immune directed pathways. 1,2 When combined, daratumumab modulates the immune system to create a more favourable immune microenvironment and enhances T-cell fitness and activation, amplifying teclistamab-mediated killing of myeloma cells. 1,2 This combination improves patient outcomes by using immunotherapies earlier in the treatment journey when patients’ immune systems are more robust. 1, 2 Expert and company perspectives support the earlier use of teclistamab combination in multiple myeloma care “Unprecedented data show a meaningful extension in overall survival and minimal progression events observed after the first six months. More than 90% of patients receiving the combination who were progression-free at six months remained progression-free at three years, highlighting the potential for durable long-term disease control.” said Ester in ’t Groen, EMEA Therapeutic Area Head, Haematology, Johnson & Johnson. “This CHMP opinion marks an important step towards establishing the off-the-shelf immunotherapy combination of teclistamab plus daratumumab as a new standard of care earlier in the treatment pathway for multiple myeloma.” “At Johnson & Johnson our ambition is to leverage the full potential of our comprehensive multiple myeloma portfolio, to strengthen patient outcomes at every stage of the treatment continuum,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "By advancing innovative immunotherapies such as teclistamab and combining them with a well-established standard of care like daratumumab, we are building on our deep scientific expertise to deliver more integrated, combination-based approaches that can continue to raise expectations for patient care.” Teclistamab plus daratumumab SC achieves meaningful and sustained improvements in patient outcomes The CHMP recommendation is supported by data from the Phase 3 MajesTEC-3 study ( NCT05083169 ), evaluating the efficacy and safety of teclistamab plus daratumumab subcutaneous (SC) formulation versus investigator’s choice of daratumumab SC and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients who have received 1–3 prior lines of therapy. 3 At nearly three years of follow-up, results show an 83.4% reduction in the risk of disease progression or death in patients treated with teclistamab plus daratumumab SC, compared to standard of care (hazard ratio [HR], 0.17; 95% confidence interval [CI], 0.12-0.23; p <0.0001). 1 More than 90% of patients who remained progression-free at six months (n=249) remained progression-free at three years, demonstrating sustained disease control over time. 1 Overall survival (OS) favoured teclistamab plus daratumumab SC (HR, 0.46; 95% CI, 0.32-0.65; p <0.0001), with treatment benefit observed across all prespecified subgroups. 1 ,2 At three years, OS rates were 83.3% for the combination and 65.0% for standard of care. 1 Both progression-free survival and OS benefits were clinically meaningful and statistically significant. 1 Manageable safety pro with teclistamab combination Teclistamab plus daratumumab SC demonstrated a safety pro with the well-known profiles of the individual therapies. 1 , 3 , 4 All cases of cytokine release syndrome were Grade 1/2, did not lead to treatment discontinuation, and were manageable and resolved. 1 Rates of Grade 3/4 treatment-emergent adverse events (TEAEs) were comparable to standard of care regimens (95.1% vs. 96.6%) with cytopenia and infection most commonly observed. 1 Grade ≥3 infections decreased over time with the use of immunoglobulin supplementation and infection prophylaxis, along with a switch to monthly dosing. 2 Discontinuations due to TEAEs were low and similar between study arms (4.6% vs. 5.5%). 1 About the MajesTEC-3 Study MajesTEC-3 ( NCT05083169 ) is an ongoing, Phase 3 randomised study evaluating the safety and efficacy of teclistamab plus daratumumab subcutaneous (SC) (n=291) versus investigator’s choice of daratumumab SC and dexamethasone with either pomalidomide or bortezomib (n=296) (DPd/DVd) in patients with relapsed or refractory multiple myeloma (RRMM) who have received 1–3 prior lines of therapy. 5 The primary endpoint is progression-free survival (PFS) and secondary endpoints include complete response or better (≥CR), overall response rate (ORR), minimal residual disease (MRD) negativity (10⁻⁵ by next-generation sequencing), overall survival (OS), time to worsening of symptoms (MySIm-Q), and safety. 5 The MajesTEC-3 study is a part of the MajesTEC clinical programme, which includes exploring the potential of teclistamab as a combination regimen. 5 About Teclistamab Teclistamab received European Commission (EC) approval in August 2022 for the treatment of patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. 6 In August 2023, the EC approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. 7 Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody. 3 , 8 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body’s immune system to fight cancer. 1,3 Teclistamab is currently being evaluated in several combination studies. 5 , 9,10 ,11 To date, more than 26,000 patients have been treated worldwide with teclistamab. 1 2 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics at: . ▼ In line with EMA regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. 3 About Daratumumab and Daratumumab SC Johnson & Johnson is committed to exploring the potential of daratumumab for patients with multiple myeloma across the spectrum of the disease. In August 2012 , Janssen Biotech, Inc., a Johnson & Johnson company, and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of multiple myeloma, having been used in the treatment of more than 748,000 patients worldwide. 1 3 Daratumumab was the first CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma. 5, 1 4 Daratumumab SC was also the first oncology injectable approved for administration by patients living with multiple myeloma or their caregivers from the fifth dose, if determined to be appropriate by their healthcare professional and following proper training. 5, 15 Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE ® drug delivery technology. 5 CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease. 5 ,16 Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death. 5 Daratumumab may also have an effect on normal cells. 5 Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings across all newly diagnosed multiple myeloma patients, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival. 17,18,19,20,21,22,23,24,25,26 For further information on daratumumab, please see the Summary of Product Characteristics at: . About Multiple Myeloma Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 2 7 ,2 8 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications. 2 9 , 30 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died. 31 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy, while remissions become progressively shorter. 32 , 33 ,3 4 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage. 3 5 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Follow us at . Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab and daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Key Search Terms MajesTEC-3 Phase 3 clinical trial TECVAYLI Teclistamab DARZALEX Daratumumab Teclistamab and daratumumab combination TECVAYLI and DARZALEX combination Relapsed and or refractory multiple myeloma (RRMM) Early relapse multiple myeloma Second line multiple myeloma treatment First relapse therapy for multiple myeloma Treatment resistance in multiple myeloma Progression-free survival (PFS) in multiple myeloma Overall survival (OS) in multiple myeloma Multiple myeloma Bispecific antibody therapy CD38-targeted therapy BCMA-targeted bispecific therapy Combination immunotherapy EMEA haematology pipeline Multiple myeloma innovation Multiple myeloma treatment END References: 1 Costa L, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2026;394(8):739-752. 2 Mateos MV, et al. Phase 3 Randomized Study of Teclistamab plus Daratumumab Versus Investigator’s Choice of Daratumumab and Dexamethasone with either Pomalidomide or Bortezomib (DPd/DVd) in patients (pts) with Relapsed Refractory Multiple Myeloma (RRMM): Results of the MajesTEC-3 Study. Oral Presentation #06. American Society of Hematology (ASH) Annual Meeting; 06-09 December, 2025. 3 European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: . Last accessed: June 2026. 4 European Medicines Agency. DARZALEX Summary of Product Characteristics. Available at: . Last accessed: June 2026. 5 ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: . Last accessed: June 2026. 6 Johnson & Johnson.com. Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma. Available at: . Last accessed: June 2026. 7 Johnson & Johnson.com. European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab). Available at: . Last accessed: June 2026. 8 Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;287(6):494-505. 9 ClinicalTrials.gov. A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: . Last accessed: June 2026. 10 ClinicalTrials.gov. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: . Last accessed: June 2026. 11 ClinicalTrials.gov. A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: . Last accessed: June 2026. 12 J&J Data on File. Number of Patients Treated with TECVAYLI Worldwide as of March 2026. 13 J&J Data on File. Number of Patients Treated with DARZALEX ® Worldwide as of December 2025. 14 Janssen EMEA. European Commission Grants Marketing Authorisation for DARZALEX ® (Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications. Available at: . Last accessed: June 2026. 15 J&J Data on File. DARZALEX® is the first oncology injectable approved for self-administration by patients or caregivers as of March 2026. 16 Fedele G, et al. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNy cytokines and proliferation. Mediators Inflamm. 2013;564687. 17 Moreau P, et al. Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-label, Phase 3 Study. Lancet. 2019;394(10192):29-38. 18 Facon T, et al. MAIA Trial Investigators. Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. 19 Mateos MV, et al. Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-label, Phase 3 Trial. The Lancet. 2020;395(10218):132-141. 20 Dimopoulos MA, et al. APOLLO Trial Investigators. Daratumumab Plus Pomalidomide and Dexamethasone Versus Pomalidomide and Dexamethasone Alone in Previously Treated Multiple Myeloma (APOLLO): An Open-label, Randomised, Phase 3 Trial. Lancet Oncol. 2021;22(6):801-812. 21 Palladini G, et al. Daratumumab Plus CyBorD for Patients with Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. Blood. 2020;2;136(1):71-80. 22 Chari A, et al. Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood. 2017;130(8):974-981. 23 Bahlis NJ, et al. Daratumumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-up of POLLUX, A Randomized, Open-label, Phase 3 study. Leukemia. 2020;34(7):1875-1884. 24 Mateos MV, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma: Three-Year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509-518. 25 Usmani S Z, et al. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study. Oral Presentation. 21 st International Myeloma Society (IMS) Annual Meeting. September 25 – 28, 2024. 26 Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024; 390(4):301-313. 27 Abdi J, et al. Drug Resistance in Multiple Myeloma: Latest Findings on Molecular Mechanisms. Oncotarget. 2013;4(12):2186-2207. 28 Myeloma UK. What is myeloma? Available at: . Last accessed: June 2026. 29 Lungu O, et al. Mechanistic insights into bone destruction in multiple myeloma: cellular and molecular perspectives. Journal of Bone Oncology. 2025;51:100668. 30 Mayo Clinic. Multiple Myeloma. Available at: . Last accessed: June 2026. 31 ECIS - European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2022, by Country. Multiple Myeloma. Available at: . Last accessed: June 2026. 32 Bhatt P, et al. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347. 33 Hernández-Rivas JÁ, et al. The Changing Landscape of Relapsed and/or Refractory Multiple Myeloma (MM): Fundamentals and Controversies. Biomark Res. 2022;10(1):1-23. 34 McCurdy A, et al. Redefining attrition in multiple myeloma (MM): a Canadian myeloma research group (CMRG) analysis. Blood Cancer Journal. 2023;13(1):111. 35 American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis and Staging. Available at: . Last accessed: June 2026. CP-583164 June 2026 CONTACT: Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: Jess Margevich investor-relations@its.jnj.com

Clinical ResultPhase 3Drug ApprovalLicense out/inImmunotherapy

19 Jun 2026

·www.biospace.com

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa SC following the EU Paris, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM). The approved indications for Sarclisa SC in Japan include in combination with pomalidomide and dexamethasone (Pd), or with carfilzomib for the treatment of relapsed or refractory MM (R/R MM) and in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM). A regulatory submission for the CirCLIQ on-body injector (OBI), based on the enFuse platform and submitted by Enable Injections, is under review in Japan. If approved, Sarclisa SC could become the first anticancer treatment to be administered via an OBI, and the first MM medicine in Japan to offer both manual SC injection and OBI administration. In recent years, new MM diagnoses have increased steadily in Japan, creating a need for new treatment approaches particularly in the front-line setting. MM is the third most common hematologic malignancy in Japan. “Today’s approval of Sarclisa subcutaneous represents an important evolution in how we deliver care for multiple myeloma patients in Japan,” said Olivier Nataf , Global Head of Oncology at Sanofi. “This new formulation significantly eases treatment burden and enhances convenience for patients compared to intravenous administration – with the potential to become Japan's first anticancer therapy to be administered via an on-body injector.” The approval is based on results from the IRAKLIA phase 3 study in R/R MM (clinical study identifier: NCT05405166 ), which demonstrated non-inferiority of the SC formulation compared to IV, as well as supportive studies . In addition to manual SC injection, these studies evaluated Sarclisa SC administered through an OBI, and were conducted using Enable Injections’ enFuse hands-free OBI, an automated injector for subcutaneous delivery of Sarclisa. In the IRAKLIA study, Sarclisa SC administered via an OBI in combination with pomalidomide and dexamethasone (Pd) resulted in a 71.1% objective response rate (ORR), compared to 70.5% with Sarclisa IV-Pd, establishing non-inferiority (risk ratio: 1.008; 95% confidence interval: 0.903-1.126; p=0.0006), in adult patients with R/R MM who had received at least one prior line of treatment. The overall safety pro Sarclisa SC-Pd observed in this study was consistent with the established safety pro Sarclisa IV-Pd. While 25% of patients treated with Sarclisa IV-Pd experienced infusion reactions, 1.5% of patients treated with Sarclisa SC-Pd experienced those reactions. No new safety concerns were observed, except for low-grade local injection site reactions (ISRs) that occurred in 0.4% of OBI injections (n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2. The most common grade ≥3 non hematologic adverse events were pneumonia (14.8% OBI, 15.5% IV), COVID-19 (2.7%, 1.9%), and upper respiratory tract infection (1.5% both arms). The most common grade ≥3 hematologic laboratory abnormalities were neutropenia (84.7% OBI, 74.3% IV), thrombocytopenia (26.1%, 23%), and anemia (17.6%, 19.5%). In Japan, Sarclisa IV is currently approved across five indications, including in combination with VRd in NDMM, as well as four different treatment regimens in R/R MM (in combination with Pd, in combination with carfilzomib and dexamethasone (Kd), in combination with dexamethasone alone, or as a monotherapy). Sarclisa SC administered via both the CirCLIQ OBI and manual injection was approved in the EU for the treatment of MM patients across all currently approved indications and combinations for Sarclisa IV formulation in June 2026. An application for Sarclisa SC administered via both OBI and manual injection is currently under review in the US. About the IRAKLIA study IRAKLIA (clinical study identifier: NCT05405166 ) was a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of Sarclisa administered at a fixed dose SC via OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The co-primary outcomes assessed were ORR, defined as the proportion of patients with stringent complete response (CR), CR, very good partial response, and partial response according to the 2016 International Myeloma Working Group criteria assessed by Independent Review Committee, and observed Sarclisa mean concentration before dosing (Ctrough) at steady state (pre-dose at cycle 6, dose 1 [C6D1]), defined as observed Sarclisa plasma concentrations. About Enable Injections Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse ® On-Body Delivery System. An innovative wearable technology, the enFuse system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit . About Sarclisa Sarclisa (isatuximab) has been approved in almost 60 countries across four indications for certain patients with NDMM and R/R MM. Sarclisa-based regimens have been prescribed to treat more than 70,000 patients worldwide. Sarclisa SC is approved in the EU and the UK in combination with approved standard-of-care regimens for the treatment of patients with MM across all currently approved indications for Sarclisa IV in these countries. It is the first anticancer treatment to be administered through an OBI, and the only anti-CD38 monoclonal antibody available in MM to offer the flexibility of both SC OBI and manual injection administration. Sarclisa SC is approved in Japan in combination with VRd, for the treatment of adult patients with NDMM, as well as Pd and Kd for the treatment of patients with R/R MM. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit . About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com Ekaterina Pesheva | +1 410 926 6780 |  ekaterina.pesheva@sanofi.com Investor Relations Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Yun Li | +33 6 84 00 90 72 | yu.li3@sanofi.com Sanofi forward-looking statements This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. All trademarks mentioned in this press release are the property of the Sanofi group except for enFuse and CirCLIQ. Attachment Press_Release

Clinical ResultPhase 3Drug Approval

16 Jun 2026

·firstwordpharma.com

Biopharma bites: Germany rethinks rebate reform, Talvey's melanoma win and more from Takeda, Pelago

Germany might soften stance on variable drug discountsTalvey combo slashes progression risk in earlier-line myelomaTakeda touts more benefits for orexin sleep drugPelago snaps up fellow Swedish CRO in drug discovery push Germany might soften stance on variable drug discountsGermany's government is set to abandon plans for a controversial variable drug rebate system and replace it with fixed discounts, according to a government source cited in a Reuters report Monday.The original proposal, part of a broader healthcare reform package announced earlier this year, would have required drugmakers to offer rebates that fluctuated based on overall expenditures for drugs and on revenues of the healthcare system. Officials are now expected to introduce a fixed discount structure instead so that companies can plan ahead, the source said.The move follows intense pushback from industry. Eli Lilly recently cut in half a planned €2.3-billion ($2.7 billion) investment in a German manufacturing facility, while Boehringer Ingelheim reportedly scrapped more than €900 million ($1 billion) in planned domestic investments. Pfizer CEO Albert Bourla also raised concerns directly with Chancellor Friedrich Merz.The rebate debate is part of a wider effort by Health Minister Nina Warken to close a projected €20-billion ($23.2 billion) funding gap in Germany's public health insurance system and head off a hike in mandatory health insurance premiums. Last week, she insisted that pharma companies must contribute to cost-containment measures and argued that Germany was nevertheless still an attractive location for drugmakers.-Anna BratulicTalvey combo slashes progression risk in earlier-line myelomaJohnson & Johnson reported Phase III results showing that its GPRC5D-targeting bispecific antibody Talvey (talquetamab) can significantly improve outcomes when combined with Darzalex Faspro (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.In the MonumenTAL-3 study, Talvey plus Darzalex Faspro with pomalidomide reduced the risk of disease progression or death by up to 72% at a median follow-up of two years, compared to the standard regimen of Darzalex Faspro, pomalidomide and dexamethasone. Without pomalidomide, Talvey plus Darzalex Faspro cut the risk by 67%.Progression-free survival rates over the two-year follow-up reached 81.3% for the Talvey-Darzalex-pomalidomide regimen and 77.6% for the Talvey-Darzalex doublet, compared to 51.2% for the control arm. Overall survival rates at 24 months were 89.2% and 87.9%, respectively, versus 79.1% for standard therapy. Findings were reported at the European Hematology Association (EHA) conference and published in the NEJM.Talvey won US and EU approval in 2023 for heavily pretreated multiple myeloma. J&J said it has filed a supplemental BLA with the FDA, and a similar application with the EMA, seeking approval for Talvey plus Darzalex Faspro, with or without pomalidomide, for multiple myeloma patients following at least one prior therapy. -Anna BratulicTakeda touts more benefits for orexin sleep drugWith regulatory reviews already underway in the US, China and Japan, Takeda unveiled new Phase III data showing that its investigational orexin receptor 2 agonist oveporexton improved daily functioning, cognition and nighttime sleep in people with narcolepsy type 1 (NT1). The findings on secondary and exploratory measures, presented at the SLEEP 2026 conference, build on previously reported results from the FirstLight and RadiantLight studies that met all primary and secondary endpoints (see – KOL Views Q&A: Takeda's oveporexton is raising the bar for narcolepsy drugs, rival orexin agonists).Across all tested doses, Takeda said oveporexton significantly improved scores on the Functional Impacts of Narcolepsy Instrument (FINI), a measure spanning tiredness, cognition, cataplexy and social activities, as well as everyday activities and responsibilities. Most treated patients reached or exceeded published normative thresholds across the six FINI domains after 12 weeks of treatment.The company also highlighted improvements in cognitive symptoms. About 70% of patients on oveporexton reported no significant cognitive difficulties on the FINI cognitive function domain, compared to about 15% of placebo recipients. On exploratory nighttime symptoms, oveporexton improved sleep quality, with most patients reporting no hallucinations or sleep paralysis. Patients also experienced meaningful reductions in disturbed nighttime sleep from baseline.-Anna BratulicPelago snaps up fellow Swedish CRO in drug discovery pushPelago Bioscience, a contract research organisation (CRO) specialising in cell-based target engagement assays, has acquired fellow Swedish firm RG Discovery — founded by ex-AstraZeneca scientists — with the aim of creating a unified platform to accelerate drug discovery programmes across the full design-make-test-analyse cycle.The acquisition — financial terms of which were undisclosed — adds RG's medicinal chemistry, custom synthesis and integrated drug discovery expertise to Pelago's proprietary Cellular Thermal Shift Assay (CETSA)-based platform. The combined offering aims to eliminate inter-vendor handoffs that typically slow progression of molecules from hit identification through lead optimisation."We can offer customers a single scientific partner capable of designing and synthesising compounds, evaluating target engagement in living cells, and rapidly feeding those insights back into the next design cycle," said Michael Dabrowski, chief executive of Pelago.-Pavan Kamat

Clinical ResultPhase 3AcquisitionDrug Approval

100 Deals associated with Pomalidomide

External Link

KEGG	Wiki	ATC	Drug Bank
D08976	Pomalidomide	L04AX06	DB08910

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kaposi Sarcoma	United States	Bristol Myers Squibb Co.	14 May 2020
Refractory Multiple Myeloma	Australia	Celgene Pty Ltd.	01 Jul 2014
Relapse multiple myeloma	Australia	Celgene Pty Ltd.	01 Jul 2014
Multiple Myeloma	United States	Bristol Myers Squibb Co.	08 Feb 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Myelofibrosis	Phase 3	United States	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	China	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Japan	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Australia	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Austria	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Belgium	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Canada	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	France	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Germany	Celgene Corp.	08 Sep 2010
Primary Myelofibrosis	Phase 3	Italy	Celgene Corp.	08 Sep 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05922501 (ISABELA, ASCO2026)	Phase 2	Relapse multiple myeloma	17	IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin + IsatuximabDexamethasonePomalidomideBelantamab mafodotin	dxahtzmzuy(thluglaarb) = Grade 3-4 hematologic adverse events (AEs) included neutropenia (53%), thrombocytopenia (29%), and anemia (12%). Common non-hematologic AEs (all; grade 3-4) included blurred vision (65%; 6%); fatigue (65%; 0%); hypertension (59%; 6%); diarrhea (53%; 0%); and AST/ALT increase (47%; 6%). Infections occurred in 35% with no grade ≥3 events. gmmyvroxwa (bynouggrgk ) View more	Positive	29 May 2026
				Dexamethasone (CD38-antibody-naïve patients)
NCT01665794 (ASCO2026)	Phase 2	Relapse multiple myeloma	28	Daratumumab+Carfilzomib+Pomalidomide+Dexamethasone	cfowlavmid(dcqnatwbwo) = jvbqmdjrlk zjakfpisel (lkbdnvtkan, 22 - 59) View more	Positive	29 May 2026
				Daratumumab+Carfilzomib+Pomalidomide+Dexamethasone (high risk group)	xcunovbixb(qszhsgfkwv) = qvcuahbenh jeacsticsb (njmlbrsvtv ) View more
NCT04902443 (ASCO2026)	Phase 1	Neoplasms	16	NivolumabPomalidomide + NivolumabPomalidomide	uwvcdgriev(fvczgqwoul) = The only dose-limiting toxicity was observed in 1 pt with metastatic anal cancer in DL1 who developed G3 dyspnea xobrvvgjfx (hwqopkpzig ) View more	Positive	29 May 2026
NCT01946477 (POM MM 014 \| MM-014 \| MM-014 cohort B, CTgov)	Phase 2	Refractory Multiple Myeloma	186	Dex+lenalidomide+POM+Dexamethasone (Cohort A)	qwqrpomkgq = ijveudzyfg dbcsbqpwop (bizhihkkkb, tkcxvwgtkb - sydtufsatc) View more	-	22 May 2026
				Dex+lenalidomide+Daratumumab+POM+Dexamethasone (Cohort B)	qwqrpomkgq = zizlfsmbog dbcsbqpwop (bizhihkkkb, ylatvzdfla - bbwoszpkow) View more
NCT04484623 (DREAMM-8, EHA2026)	Phase 3	Relapse multiple myeloma	302	Belantamab mafodotin, pomalidomide, and dexamethasone (BPd)	chnrhduxtw(zebaxetoie) = mwqdmhipad gjfkduedfp (ajaiizkqhd, NR - NR) View more	Positive	21 May 2026
				Pomalidomide, bortezomib, and dexamethasone (PVd)	chnrhduxtw(zebaxetoie) = qmxeasujzs gjfkduedfp (ajaiizkqhd, 42.7 - NR) View more
NCT04302324 (CTgov)	Phase 2	Multiple Myeloma	11	Daratumumab SC+Pomalidomide+Clarithromycin+Dexamethasone	mzgfgyxsxx = cvflpxdixe mbxfibllgm (ojulppiujl, elhpmmhfle - rjxemdsxbz) View more	-	20 May 2026
EHA2026	Not Applicable	POEMS Syndrome	9	Pomalidomide plus Dexamethasone	gbooiiszry(gdrytzhces) = The pomalidomide plus dexamethasone regimen was well tolerated, with no treatment-related deaths and no grade 3 or 4 hematological or non-hematological toxicities. knkomwpicg (rkajhdwibz )	Positive	12 May 2026
EHA2026	Not Applicable	Multiple Myeloma Maintenance	73	Pomalidomide	mvtvqjlyie(hjkmmihtid) = cnilfnofra rujnefnmoc (aabbvicmgs ) View more	Positive	12 May 2026
				Pomalidomide (standard-risk disease)	mvtvqjlyie(hjkmmihtid) = wozknpjiul rujnefnmoc (aabbvicmgs ) View more
NCT07257510 (OASIS2, EHA2026)	Phase 1	Mantle-Cell Lymphoma First line	10	Orelabrutinib+Pomalidomide+Zuberitamab	qdiudnotea(uwqeflurbq) = grade 2 pulmonary infection (n=1) qgdojvdlwq (laaplconxh ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Primary Central Nervous System Lymphoma	13	Pomalidomide, rituximab, orelabrutinib, and dexamethasone (PROD)	rcacakqvot(ogyfwkpljx) = jthzzrhcxe krwnyukuwc (cupdnttmpn ) View more	Positive	12 May 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis